Viyash Scientific Delivers Strong Q1 FY27 Performance: PAT Surges 114.9% to ₹793 Million

Viyash Scientific Limited (formerly SeQuent Scientific Limited), an integrated healthcare platform spanning Formulations, Active Pharmaceutical Ingredients (APIs), and CDMO services across human and animal health, has announced its consolidated financial results for the first quarter ended June 30, 2026 (Q1 FY27). Driven by operational scale and expanding profitability across its business verticals, the company recorded strong top-line and bottom-line growth.

Consolidated Financial Highlights

For Q1 FY27, Viyash Scientific reported consolidated revenues of ₹9,464 million, representing a 19.5% year-on-year increase compared to ₹7,916 million recorded in Q1 FY26.

Operating profitability and net income metrics grew significantly during the quarter:

EBITDA (excluding ESOP costs): Reached ₹2,047 million, up 59.2% year-on-year compared to ₹1,286 million in Q1 FY26.

EBITDA Margin: Expanded by 540 basis points to 21.6%, compared to 16.2% in the corresponding quarter of the previous fiscal year.

Profit After Tax (PAT): Surged 114.9% year-on-year to ₹793 million, up from ₹369 million in Q1 FY26.

Balance Sheet Strength

The company maintained a conservative balance sheet and healthy leverage metrics, ending the first quarter with a Net Debt to EBITDA ratio of 0.1x. The results reflect continued execution along the company's integrated platform strategy across both its human and animal health operating segments.

Commenting on the Company's performance, Dr Hari Babu Bodepudi, Managing Director and Group CEO stated that "Our performance in Q1 FY27 reflects the continued success of our integration efforts and the strength of the combined entity. This quarter's results are underpinned by robust execution, improving operating leverage, and a well-defined growth strategy. The acquisition of Bio For Life in Italy is a significant step in advancing our strategic focus on the companion animal segment, providing us with market access and a platform to launch our product portfolio in key European markets. As we move forward, our focus remains on disciplined execution, operational efficiency, and strategic investments in line with our long-term strategy for sustainable growth."

Shares of Sequent Scientific Limited was last trading in BSE at Rs. 261.45 as compared to the previous close of Rs. 273.80. The total number of shares traded during the day was 368524 in over 3669 trades.

The stock hit an intraday high of Rs. 278.25 and intraday low of 256.95. The net turnover during the day was Rs. 97456250.00.

Source : Equity Bulls

Keywords

ViyashScientific SequentScientific INE807F01027 Pharmaceuticals Q1FY27 Q1FY2027 ResultUpdate